Ketamine to Treat Patients With Post-comatose Disorders of Consciousness

Status Recruiting

Clinical Trial Summary

The investigators will run a Randomized Clinical Trial with 30 patients with disorders of consciousness (DoC), with intravenous subanesthetic doses of ketamine. Patients will simultaneously undergo TMS-EEG. The piloting will be done on 3 patients, with EEG only.

Clinical Trial Description

The protocol will be organized in three phases: baseline, experimental, and follow-up. In the baseline, patients will receive a multimodal assessment [functional magnetic resonance imaging (fMRI), positron emission tomography (PET), electroencephalogram (EEG)]. The experimental phase is made of 2 sessions spaced 5 days apart: on day 1, patients will receive placebo (or ketamine), on day 5 patients will receive ketamine (or placebo). The order will be randomized and balanced. The investigators will use a targeted-controlled infusion (TCI) system to infuse a continuous subanesthetic dose of ketamine, which is known to have psychedelics effects, or a saline solution. The investigators will periodically assess for new signs of consciousness with the "simplified evaluation of consciousness disorders" (SECONDs) scale. The investigators will use transcranial magnetic stimulation coupled to EEG (TMS-EEG) to measure brain activity and calculate brain complexity. TMS-EEG will be performed from 20 minutes before the beginning of the infusion up to the max duration of the experiment (90 minutes). Another SECONDs will be performed on the following day of each session to control for carry-over effects. The primary outcomes are the emergence of new conscious behaviours and higher brain complexity following ketamine infusion. The secondary outcomes are baseline brain differences in neurophysiological and brain imaging measures between responders (new conscious behaviors or higher brain complexity) and non-responders (no new conscious behaviors or higher brain complexity). In the follow-up phase, patients' health will be evaluated at 1, 6, and 12 months. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05343507
Study type	Interventional
Source	University of Liege
Contact	Paolo Cardone, MSc
Phone	0456309880
Email	p.cardone@uliege.be
Status	Recruiting
Phase	Phase 2/Phase 3
Start date	May 1, 2022
Completion date	May 1, 2026

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05954650` - Clinical Validity of the Minimally Conscious State "Plus" and "Minus"
Suspended	`NCT04244058` - Changes in Glutamatergic Neurotransmission of Severe TBI Patients	Early Phase 1
Recruiting	`NCT05285124` - HD-tDCS Combined With Circadian Rhythm Reconstruction and Micro Expression Changes on Consciousness Recovery in Patients With Chronic Disturbance of Consciousness	N/A
Not yet recruiting	`NCT05833568` - Five-day 20-minute 10-Hz tACS in Patients With a Disorder of Consciousness	N/A
Recruiting	`NCT05219331` - Hydrocephalus Treatment on Persistent Disorder of Consciousness	N/A
Recruiting	`NCT05706831` - Music Intervention and Transcranial Electrical Stimulation for Neurological Diseases	N/A
Completed	`NCT03114397` - Long-term Effect of tDCS in Patients With Disorders of Consciousness	N/A
Active, not recruiting	`NCT03623828` - Treating Severe Brain-injured Patients With Apomorphine	Phase 2
Active, not recruiting	`NCT05734183` - Multisensorial IMmersive Experiences (MIME) in Disorders of Consciousness	N/A
Recruiting	`NCT05714215` - SECONDs' Italian Translation and Transcultural Validation
Completed	`NCT04035655` - Sub-study of the NEURODOC Project : Neurophysiological Evaluation of a Routine Care Open Label tDCS Session	N/A
Active, not recruiting	`NCT05747170` - Olfactory Stimulation in Severe Brain Injury	N/A
Active, not recruiting	`NCT03826407` - Development of a Point of Care System for Automated Coma Prognosis
Recruiting	`NCT03576248` - CONsciousness Transcranial Electric STimulation	N/A
Recruiting	`NCT03611166` - Proteomics for Chronic Disorder of Consciousness
Recruiting	`NCT05382260` - Personal Music for Disorders of Consciousness	N/A
Not yet recruiting	`NCT05820178` - tDCS and rTMS in Patients With Early Disorders of Consciousness	N/A
Completed	`NCT05536921` - Eye Tracking Technology in the Diagnosis of Neurological Patients
Completed	`NCT02647996` - Functional Connectivity Measurement After Severe Traumatic Brain Injury
Recruiting	`NCT04530968` - Metabolic Abnormalities and Intestinal Microecology in Patients With Chronic Disorders of Consciousness

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.